Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)

NCT06923345 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer
Neoadjuvant Therapies
Immune Checkpoint Therapy
Radiotherapy

Interventions

COMBINATION_PRODUCT: Reduced CTV
COMBINATION_PRODUCT: Conventional CTV

Sponsor

Sixth Affiliated Hospital, Sun Yat-sen University